| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9, 1-14, 2017 | 2967 | 2017 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015 | 743 | 2015 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016 | 472 | 2016 |
| Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ... Journal of Thoracic Oncology 11 (9), 1493-1502, 2016 | 390 | 2016 |
| Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy H Han, AD Jain, MI Truica, J Izquierdo-Ferrer, JF Anker, B Lysy, V Sagar, ... Cancer cell 36 (5), 483-497. e15, 2019 | 302 | 2019 |
| Comprehensive genomic profiling of 282 pediatric low‐and high‐grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures A Johnson, E Severson, L Gay, JA Vergilio, J Elvin, J Suh, S Daniel, ... The oncologist 22 (12), 1478-1490, 2017 | 210 | 2017 |
| Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing CH Chung, VB Guthrie, DL Masica, C Tokheim, H Kang, J Richmon, ... Annals of oncology 26 (6), 1216-1223, 2015 | 192 | 2015 |
| Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes J Chmielecki, KE Hutchinson, GM Frampton, ZR Chalmers, A Johnson, ... Cancer discovery 4 (12), 1398-1405, 2014 | 175 | 2014 |
| Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In … SM Ali, T Hensing, AB Schrock, J Allen, E Sanford, K Gowen, A Kulkarni, ... The oncologist 21 (6), 762-770, 2016 | 141 | 2016 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015; 5: 850–859 … GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Go to original source... Go to PubMed, 2015 | 115 | 2015 |
| Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes JH Chung, E Sanford, A Johnson, SJ Klempner, AB Schrock, NA Palma, ... Annals of Oncology 27 (7), 1336-1341, 2016 | 93 | 2016 |
| STUMP un “stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features … V Subbiah, C McMahon, S Patel, R Zinner, EG Silva, JA Elvin, IM Subbiah, ... Journal of Hematology & Oncology 8, 1-7, 2015 | 86 | 2015 |
| Genomic profiling of prostate cancers from men with African and European ancestry Y Koga, H Song, ZR Chalmers, J Newberg, E Kim, J Carrot-Zhang, D Piou, ... Clinical Cancer Research 26 (17), 4651-4660, 2020 | 84 | 2020 |
| First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer MP Goetz, VJ Suman, JM Reid, DW Northfelt, MA Mahr, AT Ralya, ... Journal of clinical oncology 35 (30), 3391, 2017 | 82 | 2017 |
| Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer R Vatapalli, V Sagar, Y Rodriguez, JC Zhao, K Unno, S Pamarthy, B Lysy, ... Nature communications 11 (1), 4153, 2020 | 80 | 2020 |
| Integrated analysis of multiple biomarkers from circulating tumor cells enabled by exclusion-based analyte isolation JM Sperger, LN Strotman, A Welsh, BP Casavant, Z Chalmers, S Horn, ... Clinical Cancer Research 23 (3), 746-756, 2017 | 62 | 2017 |
| Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration JA Elvin, LM Gay, R Ort, J Shuluk, J Long, L Shelley, R Lee, ZR Chalmers, ... The Oncologist 22 (4), 416-421, 2017 | 56 | 2017 |
| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9 (1): 34 ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... | 54 | |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol. Res. 2016; 4: 959–967. doi: 10.1158/2326-6066 DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... CIR-16-0143.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 48 | |
| Comprehensive genomic profiling identifies frequent drug-sensitive EGFR exon 19 deletions in NSCLC not identified by prior molecular testing AB Schrock, GM Frampton, D Herndon, JR Greenbowe, K Wang, ... Clinical Cancer Research 22 (13), 3281-3285, 2016 | 46 | 2016 |
Garrett M FramptonFoundation Medicine Inc.在 foundationmedicine.com 的电子邮件经过验证
Garrett M FramptonFoundation Medicine Inc.在 foundationmedicine.com 的电子邮件经过验证
Doron LipsonCSO, Ultima Genomics在 ultimagen.com 的电子邮件经过验证